Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Taclantis (PICS) in Metastatic Breast Cancer
NCT04332549Phase 1Withdrawn
- Sponsor
- Sun Pharma
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Paclitaxel Micelles for Injection in breast cancer (2 arms), sponsored by Sun Pharma. Primary endpoints: Maximum observed plasma concentration at 8 weeks, Area under the plasma concentration versus time curve from time 0 to the last measurable concentration at 8 weeks and 2 more. Planned start Apr 2020; status: withdrawn.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04332549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332549.